It’s “Full Speed Ahead” For Merck In HCV After $3.85B Idenix Buyout

The company expects to come charging out of the gate with a three-drug combo therapy for hepatitis C now that it has acquired a nucleotide analog to round out its portfolio. Merck is undeterred by the risks associated with the deal.